NCT01975701 - A Phase 2 Study of BGJ398 in Patients With Recurrent GBM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2013

Primary Completion Date

October 3, 2018

Study Completion Date

October 3, 2018

Conditions

Recurrent Glioblastoma or Other Glioma Subtypes

Interventions

DRUG

BGJ398

Capsule for oral use.

Trial Locations (17)

3000

Novartis Investigative Site, Leuven

3050

Novartis Investigative Site, Melbourne

8091

Novartis Investigative Site, Zurich

10032

Novartis Investigative Site, New York

28041

Novartis Investigative Site, Madrid

28050

Novartis Investigative Site, Madrid

43221

Novartis Investigative Site, Columbus

60611

Novartis Investigative Site, Chicago

75246

Novartis Investigative Site, Dallas

75251

Novartis Investigative Site, Dallas

77030

Novartis Investigative Site, Houston

90095

Novartis Investigative Site, Los Angeles

94101

University of California San Francisco Dept of Onc., San Francisco

02215

Novartis Investigative Site, Boston

3508 GA

University Medical Center Utrecht, Utrecht

08035

Novartis Investigative Site, Barcelona

08907

Novartis Investigative Site, L'Hospitalet de Llobregat